LNP 101 Day: Monday, April 14

8.00 Check-In & Coffee With a Light Breakfast

8:50 am Chair’s Opening Remarks

Deep Diving into the History, Early Successes & Key Components of LNPs to Gain a Solid Foundation for Leveraging LNPs to Deliver Therapeutics & Vaccines

9:00 am Delving into the History of Lipid Nanoparticles to Understand the Evolution of this Innovative Delivery Vehicle

Synopsis

  • Deep diving into the discovery of LNPs to understand how they were initially invented
  • Uncovering the initial formulations and purposes of LNPs through evaluation of the first patent filings which took place
  • Reviewing academic and pharmaceutical progress of LNPs, including the uncovering the development of the first FDA approved drug utilizing LNPs

9:30 am Uncovering the Roles of the Components in LNPs for Developing Stable Delivery Vehicles

  • Jivan Yewle Director, Non-Viral Delivery, Mammoth Biosciences

Synopsis

  • Evaluating the 4 components in LNPs; ionizable lipid, phospholipid, sterol and PEGylated phospholipid, for developing functional LNPs
  • Exploring the potential of adding in a 5th component, such as polymers, to improve stability
  • Improving targeting of LNPs with conjugates, peptides and more for enabling extrahepatic delivery

10:00 am An mRNA-LNP Vaccine Platform that Elicits In Vivo Immune Response Against SARS-CoV-2 with Suitable Stability

Synopsis

Details to be revealed

10.30 Morning Networking Break

Gaining Knowledge on the Fundamental Strategies for Successfully Analyzing, Formulating & Manufacturing Traditional & Innovative LNPs

11:30 am Evaluating the Fundamental Analytical Methods for Characterizing & Identifying Effective LNPs with Good Encapsulation Efficiency, Morphology & Stability

Synopsis

  • Delving into the current go-to analytical methods for understanding and characterizing LNPs
  • Uncovering the limitations and benefits of each analytical method for better understanding of LNPs
  • Utilizing Ribogreen assays and DLS to their full advantage for accurate measurement of particle size and encapsulation efficiency

12:00 pm Getting up to Speed on the Formulation Methods for Development of Traditional & Innovative LNPs

  • Kanika Suri Scientist, Takeda Pharmaceutical Co. Ltd.

Synopsis

  • Delving into the past, present and future formulation development of LNPs
  • Deep diving into the best formulation methods for reliably developing LNPs
  • Revealing a successful roadmap for translating LNPs from concept to the clinic

12:30 pm Uncovering the Fundamentals for Manufacturing LNPs with Reliable Mixing, Filtration & Purification Techniques

Synopsis

  • Delving into generic routes for scaling-up LNPs
  • Uncovering the critical quality attributes which need to be considered to enable successful scale up
  • Evaluating the currently strategies for mixing, filtering and purifying LNPs

13:00 Lunch & Networking

Uncovering the Huge Potential of LNPs to Encapsulate Many Payload Types for Developing Cures to a Large Disease Landscape

2:00 pm Panel Discussion: Leveraging LNPs to Deliver a Range of Payloads to Treat a Wide Landscape of Disease

Synopsis

  • Highlighting the range of payloads being delivered by LNPs, including mRNA, siRNA, CAR DNA, gRNA and beyond
  • Showcasing the different characteristics and specifications required to be met by LNPs to deliver the different payload types
  • Uncovering the different challenges and opportunities it comes to using LNPs for both vaccines and therapeutics

3:00 pm Reviewing the Disease Applications of LNPs to Unleash their Full Potential for Treating a Large Variety of Patients

  • Annette Bak Head, Advanced Drug Delivery, AstraZeneca

Synopsis

  • Uncovering the potential of developing innovative LNPs for treating a wide landscape of disease
  • Delving into the current clinical trials happening using LNPs to deliver genetic medicine, cell therapy, cancer and autoimmune treatments
  • Discussing the bottlenecks faced when using LNPs for diseases outside of the liver

3:30 pm End of LNP 101 Day